Introduction {#sec1-1}
============

Heart failure (HF) is categorized by a reduced left ventricular ejection fraction (LVEF) (HFrEF, LVEF \<40%) or by a preserved LVEF (HFpEF, LVEF ≥50%). However, current guidelines recognize HF with mid-range ejection fraction (HFmrEF, LVEF 40%--49%) as an entity distinct from HFrEF and HFpEF ([@ref1]). Nearly half of the population with HF worldwide has HFpEF or HFmrEF ([@ref2]-[@ref4]), and these conditions have become a major public health problem because their prevalence rate increases by 1% every year ([@ref5]), with rates of cardiovascular mortality and morbidity similar to those seen in HFrEF ([@ref6]-[@ref8]). Clinical profile, presentation, and pathophysiology of HFpEF and HFmrEF are heterogeneous and their management remains controversial. In contrast to HFrEF, no specific therapy has been shown to significantly improve the outcome of HFpEF or HFmrEF, which may be explained by heterogeneity in the underlying pathophysiological mechanisms and frequently associated co-morbidities in these population ([@ref6]). However, most of the HFpEF and HFmrEF studies have been conducted in western countries, and limited information is available in other regions of the world. The epidemiology and management of HFpEF and HFmrEF could be quite different in developing countries, such as Turkey, from that in western countries with respect to the ethnic background and etiology. The heart failure prevalence and predictors in Turkey (HAPPY) trial was the largest study in Turkey conducted on HF patients ([@ref9]). This study included 4650 randomly selected residents aged ≥35 years to determine the prevalence of HF in Turkey, based on echocardiography and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Results of the HAPPY study have shown that the prevalences of HF and asymptomatic left ventricular dysfunction were higher in Turkey than those in western countries, despite a younger Turkish population. However, this study has some methodological limitations such as underuse of echocardiography and lack of current standard definitions of HFpEF ([@ref9]). The Turkish registry for diagnosis and treatment of acute heart failure (TAKTIK) study was a prospective national survey of 36 medical centers across Turkey ([@ref10]). A total of 588 patients who were hospitalized with acute HF were enrolled. Echocardiographic data was available for 88% of patients, and the mean LVEF was 33%±13%. Preserved LVEF, defined as LVEF ≥40%, was present in 20% of patients ([@ref10]). However, demographic or clinical characteristics of HFpEF patients were not specifically analyzed in the TAKTIK study. Due to scarce data on HFpEF and no data on HFmrEF in our country, the APOLLON study aimed to provide comprehensive data including detailed clinical characteristics and medication usage on HFpEF and HFmrEF.

The results of the APOLLON trial will provide critical knowledge for understanding the disease entity, optimizing patient management, and designing clinical trials in HFpEF and HFmrEF patients.

Methods {#sec1-2}
=======

Study design and setting {#sec2-1}
------------------------

The APOLLON trial was designed as a multicenter, noninterventional (observational) study to evaluate the demographic characteristics of HFmrEF and HFpEF patients. The study will be performed by hospital-based cardiologists who regularly treat HF patients. Under the leadership of Muğla Sıtkı Koçman University Cardiology Department, 13 centers were enrolled in the study. The sample sizes of the regions included in the study are shown in [Figure 1](#F1){ref-type="fig"}. The names of the coordinators and researchers are shown in [Table 1](#T1){ref-type="table"}.

![Geographic distribution of the APOLLON study patients in Turkey (number of patients in each region are shown in parentheses)](AJC-19-311-g001){#F1}

###### 

The names of the participating researchers and centers with patient number in the APOLLON trial

  City            Researcher (Name, Surname)   Center                                                                                 Patient Number
  --------------- ---------------------------- -------------------------------------------------------------------------------------- ----------------
  Muğla           Bülent Özlek                 Muğla Sıtkı Koçman University Training and Research Hospital (Coordinating Center)     151
  Muğla           Murat Biteker                Muğla Sıtkı Koçman University Training and Research Hospital (Coordinating Center)     
  Muğla           Eda Özlek                    Muğla Sıtkı Koçman University Training and Research Hospital (Coordinating Center)     
  Muğla           Volkan Doğan                 Muğla Sıtkı Koçman University Training and Research Hospital (Coordinating Center)     
  Muğla           Oğuzhan Çelik                Muğla Sıtkı Koçman University Training and Research Hospital (Coordinating Center)     
  Muğla           Cem Çil                      Muğla Sıtkı Koçman University Training and Research Hospital (Coordinating Center)     
  Muğla           Özcan Başaran                Muğla Sıtkı Koçman University Training and Research Hospital (Coordinating Center)     
  İstanbul 1      Hicaz Zencirkıran Ağuş       Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital   115
  İstanbul 1      Serkan Kahraman              Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital   85
  İstanbul 1      Samet Sevinç                 Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital   72
  İstanbul 2      Altuğ Ösken                  Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital    90
  Ankara          Veysel Ozan Tanık            Dışkapı Yıldırım Beyazıt Training and Research Hospital                                90
  Eskişehir       Kadir Uğur Mert              Eskişehir Osmangazi University Faculty of Medicine                                     25
  Kayseri         Erkan Demirci                Kayseri Training and Research Hospital                                                 15
  Kayseri         Engin Dondurmacı             Kayseri Training and Research Hospital                                                 15
  Kırıkkale       Yunus Çelik                  Kırıkkale Yüksek İhtisas Hospital                                                      15
  Kahramanmaraş   Mehmet Tekinalp              Kahramanmaraş Necip Fazıl City Hospital                                                132
  Çorum           Lütfü Bekar                  Hitit University Çorum Erol Olçok Training and Research Hospital                       50
  Zonguldak       Mustafa Ozan Çakır           Bülent Ecevit Universiy Medical Faculty                                                51
  Kars            İbrahim Rencüzoğulları       Kafkas University Medical Faculty                                                      69
  Şanlıurfa       Bedri Caner Kaya             Mehmet Akif İnan Training and Research Hospital                                        68
  Adıyaman        Hakan Tibilli                Adıyaman University, Training and Research Hospital                                    22
  Total                                                                                                                               1065

The study will not stipulate any diagnostic or treatment procedures. The study was approved by the Institutional Review Board or Local Ethics Committee (Muğla Sıtkı Koçman University) and registered at ClinicalTrials.gov (NCT03026114). Sample size is calculated based on the assumption that 50% of HF patients have HFpEF or HFmrEF. Power calculation is based on a two-sided test, with a power of 0.80, and with a significance level α of 0.05; the required sample size was 1065. From March 31, 2018, to June 30, 2018, a total of 1065 patients who presented to the outpatient cardiology clinics with New York Heart Association class II, III, or IV HF sign and/or symptoms will be enrolled in the study at 12 sites across the country. The 1^st^ Geography Congress in Turkey, held in Ankara in 1941, divided Turkey into seven separate regions based on climate, human habitat, agricultural diversity, and topography. To ensure adequate geographic diversity in patients included in the APOLLON study, the number of patients enrolled from each region will be proportional to the population of that region. The geographical distribution of hospitals across the country and the overall profile of the participating cardiology institutions will be representative of the national setting of cardiovascular care in Turkey. Participants will be enrolled during a routine ambulatory visit. The geographical distribution of hospitals across the country and the overall profile of the participating cardiology institutions will be representative of the national setting of cardiovascular care in Turkey.

Eligibility criteria {#sec2-2}
--------------------

To qualify for documentation in the study, adult outpatients must fulfill all of the following eligibility criteria:

Patients aged ≥18 years at the time of enrollment;Patients willing to participate and provide written informed;Patients with a LVEF ≥40%;Signs and symptoms of HF are defined in [Table 2](#T2){ref-type="table"}. One symptom must be present at the time of screening and one sign must be present in the last 12 months. Heart failure eligibility should be carefully monitored and documented in the subject's medical records; Table 2Common signs and symptoms of heart failureSymptomsSigns**TypicalMore Specific**BreathlessnessElevated jugular venous pressureOrthopnoeaHepatojugular refluxParoxysmal nocturnal dyspneaThird heart soundReduced exercise toleranceFatigue, tirednessAnkle swelling**Less typicalLess specific**Nocturnal coughWeight gain (\>2 kg/week)WheezingWeight loss or cachexiaBloated feelingCardiac murmurLoss of appetitePeripheral edemaConfusionPulmonary crepitationsDepressionTachycardiaPalpitationsTachypnoeaDizzinessHepatomegalySyncopeAscitesBendopneaOliguria

Brain natriuretic peptide (BNP) level in the last 30 days \>35 pg/mL or N-terminal pro-B-type natriuretic peptide (NT-proBNP) level \>125 pg/mL.

Exclusion criteria {#sec2-3}
------------------

Patients with a LVEF \<40%;Significant chronic pulmonary disease according to the investigator;Primary hemodynamically significant uncorrected valvular heart disease, obstructive or regurgitant;Patients with any history of surgically corrected heart valve diseases (e.g., mechanical or bioprosthetic heart valves);Myocardial infarction, stroke, or coronary artery bypass graft surgery in the past 90 days;Percutaneous coronary intervention or pacemaker implantation in the past 30 days;Heart transplant recipient;Known infiltrative or hypertrophic obstructive cardiomyopathy or known pericardial constriction;Congenital heart disease;Cor pulmonale;Pregnancy.

Measurements {#sec2-4}
------------

[Table 3](#T3){ref-type="table"} provides a summary of the items that appeared in the APOLLON survey questionnaire. The demographic, clinical, and other objective data will be collected for each participant at the visit and will include the following:

###### 

Summary of the APOLLON survey questionnaire

  Number of patients                  1065
  ----------------------------------- ------------------------------------------------------------------------------
  **Study type**                      Multicenter, cross-sectional, observational
  **Patient population**              HFpEF and HFmrEF patients who presented to the outpatient cardiology clinics
  **Demographic information**         Gender
                                      Age
                                      Body mass index
                                      Smoking history
                                      Place of residence (rural or urban)
                                      Level of education
                                      Alcohol use
                                      Hospitalization history of heart
                                      failure in the last 1 year
  **Patient's complaint**             Breathlessness (NYHA class)
                                      Orthopnoea
                                      Paroxysmal nocturnal dyspnea
                                      Reduced exercise tolerance
                                      Bendopnea
                                      Palpitations
                                      Fatigue, tiredness, increased
                                      time to recover after exercise
                                      Ankle swelling
                                      Nocturnal cough
                                      Syncope
                                      Dizziness
                                      Chest pain
  **Physical examination findings**   Blood pressure
                                      Heart rate
                                      Jugular venous pressure
                                      Cardiac murmur
                                      Third heart sound (gallop rhythm)
                                      Peripheral edema
                                      (ankle, sacral, scrotal)
                                      Pulmonary crepitations
                                      Tachypnoea
                                      ECG abnormality
                                      Ascites
                                      Tissue wasting (cachexia)
  **Laboratory data**                 B-type natriuretic peptide and
                                      N-terminal pro-B-type natriuretic
                                      peptide Fasting blood glucose
                                      Blood urea nitrogen
                                      Serum creatinine
                                      Serum sodium
                                      Sorum potassium
                                      Serum calcium
                                      Serum uric acid
                                      Thyrotrophin-stimulating hormone
                                      Hemoglobin
                                      Leukocyte
                                      C-reactive protein
                                      Ferritin
  **Echocardiography findings**       e' (a mean septal and lateral wall)
                                      E/e'
                                      LV end diastolic diameter
                                      LV end sistolic diameter
                                      Interventricular septum diameter
                                      LV posterior wall diameter
                                      Left atrium volume index
                                      Pulmonary artery systolic pressure
                                      Mitral regurgitation
                                      Mitral stenosis
                                      Aortic stenosis
                                      Aortic regurgitation
                                      Tricuspid regurgitation
  **Comorbidities**                   Atrial fibrillation
                                      Hypertension
                                      Diabetes mellitus
                                      Renal failure
                                      Obstructive sleep apnea syndrome
                                      Hyperlipidemia
                                      History of myocardial infarction
                                      Coronary artery disease
                                      Cardiac pacemaker
                                      Peripheral artery disease
                                      Cerebrovascular disease
                                      Chronic obstructive
                                      pulmonary disease
                                      Liver disease
                                      Depression
                                      Malignancy
  **Medication**                      Angiotensin converting
                                      enzyme-inhibitor
                                      Angiotensin receptor blocker
                                      B blocker
                                      Aldosterone receptor antagonist
                                      Ivabradine
                                      Amiodarone
                                      Propafenone
                                      Calcium channel blockers
                                      Digoxin
                                      Statin
                                      Loop diuretics
                                      Thiazide diuretics
                                      Nitrate
                                      Antiplatelet therapy
                                      Anticoagulant therapy
                                      ARNI
                                      Nonsteroidal anti-inflammatory drugs
                                      Oral antidiabetic drugs
                                      Insulin

HFpEF - Heart failure with preserved left ventricular ejection fraction, HFmrEF - heart failure with mid-range ejection fraction, NYHA - New York Heart Association, ARNI - Angiotensin II Receptor Blocker Neprilysin Inhibitor

Age, sex, smoking history, level of education, place of residence (rural or urban), body mass index, and alcohol use;Previous therapies or interventions to treat HF;Concomitant medications;Vital signs and laboratory tests including B-type natriuretic peptide (BNP) and/or NT-proBNP levels;Signs and symptoms at presentation (e.g., paroxysmal nocturnal dyspnea, orthopnoea, dyspnea on exertion, rales, ankle edema, neck-vein distention, pleural effusion, pulmonary edema, appetite loss, cardiac murmur, third heart sound, and New York Heart Association functional classification on admission);Comorbidities (e.g., hypertension, diabetes, atrial fibrillation, coronary artery disesase, prior stroke, renal failure, chronic obstructive pulmonary disease, and obstructive sleep apnea syndrome);Transthoracic echocardiography and 12-lead ECG results at rest for all patients;

Definition of HF in the study population {#sec2-5}
----------------------------------------

HF is defined as the presence of signs and/or symptoms of congestive heart failure, elevated BNP levels (\>35 pg/mL) or NT-proBNP levels (\>125 pg/mL).

All patients will be screened by transthoracic echocardiography, and LVEF will be assessed using the conventional apical two- and four-chamber views and the modified Simpson's method. Patients will classified according to the new terminology of the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic HF as HFpEF (LVEF ≥50%) and HFmrEF (LVEF 40%---49%) ([@ref1]). For the determination of HFpEF and HFmrEF, at least one additional echocardiographic criterion including relevant structural heart disease or diastolic dysfunction is required ([Fig. 2](#F2){ref-type="fig"}). Key structural alterations were accepted as a left atrial volume index (LAVI) \>34 mL/m^2^ or a left ventricular mass index (LVMI) ≥115 g/m^2^ for males and ≥95 g/m^2^ for females. Key diastolic dysfunction criteria were accepted an E/e′ ≥13 and a mean e' septal and lateral wall \<9 cm/s.

![Flow diagram illustrating patients meeting entry criteria and definition of heart failure](AJC-19-311-g002){#F2}

Statistical analyses {#sec2-6}
--------------------

Summary statistics will be provided as percentages (%) or as mean with standard deviations (SD). Baseline continuous variables will be presented as mean±SD or median and interquartile range, depending on the distribution of the data; categorical data will be presented as counts and percentages. We will compare the categorical variables using the χ^2^ test and the continuous variables using the t-test or the Mann--Whitney U-test, as appropriate. Univariate and multiple regression analyses will be used to calculate odds ratio and 95% confidence interval. Analyses are and will be performed with SPSS system software (version 24.0 or higher).

Discussion {#sec1-3}
==========

Approximately 50% of all HF patients exhibit a reduced LVEF termed HFrEF and the others may be classified into HFmrEF or HFpEF ([@ref1]). Data from the US and Europe suggest that the demographic characteristics, symptom profile, comorbidities, laboratory values, and outcomes of HFmrEF and HFpEF patients may differ from those of HFrEF patients ([@ref11], [@ref12]). However, to our knowledge, there have been no clinical trials examining patients' clinical profiles and management with HFmrEF or HFpEF in Turkey. Therefore, the APOLLON trial aimed to ([@ref1]) demonstrate the current status of the clinical background of HFmrEF and HFpEF patients, ([@ref2]) determine standard clinical practice on HF management, and ([@ref3]) analyze the appropriateness of medical therapy in HFmrEF and HFpEF patients in a large, multicenter, and observational trial.

Several high-quality epidemiologic studies have shown that HFpEF patients are predominantly elderly, more likely to be females, and have a high prevalence of comorbidities such as hypertension, diabetes mellitus, atrial fibrillation, and coronary artery disease ([@ref5], [@ref8]). These studies have also demonstrated that HFpEF is an emerging epidemic and survival with HFpEF is poor, especially after hospitalization for HF.

After the release of 2016 ESC guidelines for the diagnosis and treatment of acute and chronic HF, numerous studies have been performed to identify demographic and clinical chracteristics of HFmrEF patients and to investigate whether these patients are characterized by diverse features, different comorbid conditions, and distinct therapeutic needs compared with HFpEF or HFrEF patients ([@ref11]-[@ref13]). Recent studies have shown that the prevalence of HFmrEF in the HF population is between 13% and 24% ([@ref14]-[@ref16]).

Get With The Guidelines (GWTG) registry revealed the data of \>40,000 hospitalized HF patients and showed that 47% of the patients had HFpEF, 14% had HFmrEF, and 39% had HFrEF ([@ref17]). HFmrEF patients had characteristics more similar to HFpEF patients than HFrEF patients, and treatment for HFmrEF patients was in a pattern that resembled treatment for HFpEF patients ([@ref17]). HFrEF patients had slightly increased mortality at 1 year (37.5%) compared with HFmrEF (35.1%) and HFpEF (35.6%) patients ([@ref17]). In another study of hospitalized HF patients, HFmrEF patients had mortality rates of 21.3% at 1 year, which was intermediate between those of HFpEF (22.2%) and HFrEF (25.5%) patients ([@ref8]). Farmakis et al. ([@ref18]) published the results of the Acute Heart Failure Global Registry of Standard Treatment trial that included 4953 patients hospitalized for HF in nine countries. This study showed that 811 (24.9%) patients had HFmrEF and 748 (23.0%) HFpEF. The majority of HFmrEF patients were males (64.9%), and 29.3% of them aged \>75 years. The proportion of elderly and female patients was higher in these patients compared to HFrEF patients. However, the number of elderly and female patients was lower in HFmrEF patients compared to patients with HFpEF. Compared with HFrEF and HFpEF patients, HFmrEF patients had a higher prevalence of hypertension and dyslipidemia, an intermediate prevalence of coronary artery disease, and a lower prevalence of chronic renal disease ([@ref18]). The results of current observational and population-based studies suggested that HFrEF and HFmrEF patients show higher percentages of ischemic heart disease and idiopathic dilated cardiomyopathy, and hypertensive heart disease and valvular heart disease are the more common etiologies in HFpEF ([@ref11], [@ref19]). The Swedish Heart Failure registry showed that the rates of ischemic heart disease were 60% for HFrEF, 61% for HFmrEF, and 52% for HFpEF ([@ref20]).

The ESC Heart Failure Long-term Registry revealed the differences in medical therapy in these three groups of HF patients ([@ref19]). Use of beta-blockers and angiotensin-converting enzyme inhibitors was approximately 90% in both HFrEF and HFmrEF compared with approximately 75% in HFpEF. Use of mineralocorticoid receptor antagonists was approximately 70% in HFrEF, 55% in HFmrEF, and 35% in HFpEF. Ivabradine was prescribed to approximately 10% of HFrEF and HFmrEF patients and 5% of HFpEF patients.

Inspite of the general belief that HFmrEF patients are considered to be the "middle child of HF" ([@ref21]) or transition of HFrEF to HFpEF (and vise versa), at least in some studies, HFmrEF seems to be more similar to HFrEF in terms of ischemic etiology, biomarker profile, and response to treatment ([@ref22]).

In summary, although the 'intermediate' clinical profile of HFmrEF between HFrEF and HFpEF would support the conclusion that HFmrEF is a distinct clinical entity, there is no data about HFmrEF or HFpEF in our country. The APOLLON study will be the first study in HFpEF and HFmrEF patients in Turkey. The findings of this study will provide important real world evidence as well as potentially providing a better understanding of the burden of HFpEF and HFmrEF and the variability in disease management in individual units.

Study limitations {#sec2-7}
-----------------

The APOLLON study is a limited cross-sectional survey that will provide a snapshot of HFmrEF or HFpEF. Therefore, it will not be possible to observe the course of the disease, and information regarding prognosis data will be limited. Another limitation is that the coverage of the study is limited to outpatient cardiology clinics. Lastly, we have excluded patients with normal BNP or NT-proBNP levels. However, recent studies have shown that up to 30% of patients with confirmed HFpEF have normal natriuretic peptide levels ([@ref23]-[@ref25]).

Conclusion {#sec1-4}
==========

This study is designed to evaluate current demographic, clinical, echocardiographic, and biomarker characteristics and clinical practice in HFpEF and HFmrEF patients. The results of the APOLLON study will provide direction for future research and guide the clinical management of these patients.
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